



Software for
Business Intelligence

BizInt Smart Charts

Creating Impactful Reports in STNext and BizInt Smart Charts

STN Patent Forum, May 2022

John Willmore, BizInt Solutions



BizInt Smart Charts


Agenda

- Basics of Building Reports
 - Create
 - Edit
 - Export
 - Combine
 - Integrate
- Advanced Uses



Creating Charts from STNext


- Use the Reporting interface to export in BizInt format



The screenshot shows a 'Reporting' dialog box with a close button (X) in the top right corner. It is divided into two main sections. The left section, titled 'Select L#s to Include', contains a 'Clear' link, an 'Expand All' link, a dropdown arrow, a checked checkbox for 'L5 L3 AND L4', and a count '(86)'. The right section contains two sub-sections. The first, 'Select Field Template', has a 'Manage Custom Templates' link and a list of radio buttons: 'Journal', 'Patent', 'Patent and Journal', and 'Substance Report'. The second sub-section, 'Select Report Format', has a 'Hit Highlighting Options' link and a row of radio buttons: 'Standard', 'Enhanced', 'Table', 'XML', and 'BizInt'. The 'BizInt' radio button is selected, and a hand cursor icon is over it. A large blue arrow points from the right towards the 'BizInt' option.

Creating Charts from STNext

- **Pre-requisite:** Must have the software installed
- You can Open the .BPD file directly in the browser
- **Best practice:** Save the .BPD file, open from your computer
- To open: double-click; File | Import; or drag and drop



Field Selection and Order

- Make sure that the fields you might want in your report are included in your template.
- **Not a typical report format...**
 - Don't remove fields that you don't need via the template. You can select columns in BizInt Smart Charts.
 - Order of fields in your template doesn't matter.

STNext Reports and Templates

MEDLINE
Record

BIB AB

Journal
Template

BizInt
Definition

Columns

BizInt
Chart

STNext

Transcript ONmedl_willmore_epilepsy

File MEDLINE

L5ANSWER 2 OF 86MEDLINE on STN

AN2013550380MEDLINE Full-text

DNPubMed ID: 23585123

TIHippocampal gene expression profiling in a rat model of posttraumatic epilepsy reveals temporal upregulation of lipid metabolism-related genes.

AUUeda Yuto

CSSection of Psychiatry, Department of Clinical Neuroscience, Faculty of Medicine, University of Miyazaki, Miyazaki, 889-1692, Japan.

AUKitamoto Aya; Willmore L James; Kojima Toshio

SONeurochemical research. (2013 Jul) Vol. 38, No. 7, pp. 1399-406. Electronic Publication Date: 13 Apr 2013

Journal code: 7613461. E-ISSN: 1573-6903. L-ISSN: 0364-3190.

DOIhttp://dx.doi.org/10.1007/s11064-013-1037-9

CYUnited States

DTJournal; Article; (JOURNAL ARTICLE)

LAEnglish

FSMEDLINE; Priority Journals

FSPrint; Electronic


EM201401

EDEntered STN: 16 Apr 2013

Last Updated on STN: 28 Jan 2014

Indexing Added: 28 Jan 2014

Entered Medline: 24 Jan 2014



	Drug	Common Drug Name	Database	Synonyms	Highest Phase	Companies	Last Update
1	Pretium	Pretium	Donec	Velut auctor Diam gravida Lobortis leo bibendum	Phase 3	Lobortis Turpis Aliquam Sodales	2012-11-17
2	Pretium XGS	Pretium	Loareet Sem	Velut auctor Diam gravida XG-2	Phase2	Lobortis Turpis Aliquam Sodales	2012-10-01
3	Sollicitudin 4S	Sollicitudin	Donec	Quam diam Augue du	Phase 3	Egestas Condernum Lobortis Turpis	2011-12-07
4	Sollicitudin	Sollicitudin	Elifend-UR	Quam diam Augue du Ametan id lacus	Phase 3	Egestas Condernum	2011-06-07
5	Etiam Mollis	Etiam Mollis	Loareet Sem	Adipiscing Proin Mattis Faucibus laculus	Phase 3	Condernum Est	2012-01-13
6	Etiam Mollis	Etiam Mollis	Elifend-UR	Adipiscing Et Sec Proin Mattis Faucibus	Phase 2	Condernum Est	2012-01-13
7	Toror Felis	Toror Felis	Donec	Aenean lectus purus Nulla sit amet Quisque placerat 2A	Phase 2	Loareet	2011-06-03
8	Toror Felis III	Toror Felis	Loareet Sem	Aenean lectus purus Quisque placerat	Phase 2	Loareet	2011-06-03
9	Consectetur	Consectetur	Donec	Purus non urna Ugula est Quam sem ac	Phase 3	Lobortis Turpis	2012-03-01
10	Consectetur 2A	Consectetur	Nullam	Purus non urna Ugula est Quam sem ac	Phase 3	Lobortis Turpis	2012-03-01

STNext Reports and Templates

EPFULL
Record

BIB AB
CLMEN

Patent
Template

BizInt
Definition

Columns

BizInt
Chart

STNext

Transcript ON2022_0013_Transcript

File EPFULL

L5

ANSWER 1 OF 1 EPPULL COPYRIGHT 2022 LNU on STN.

AN

1992589 EPPULL EDP 20210308 ED 20210308 UP 20211125 EOTX 20210308 DED 20110331 DUPO 20211118 Full-text

TIE

PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS

TIFR

COMPOSES DE PYRAZOLO[3,4-B]PYRIDINE ET LEUR UTILISATION COMME INHIBITEURS DE PDE4

TIDE

PYRAZOLO[3,4-B]PYRIDINVERBINDUNGEN UND IHRE VERWENDUNG ALS PDE4-INHIBITOREN

IN

EDLIN, Christopher, David, GlaxoSmithKline Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY, GB
HOLMAN, Stuart, GlaxoSmithKline Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY, GB
JONES, Paul, Spencer, GlaxoSmithKline Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY, GB
KEELING, Suzanne, Elaine, GlaxoSmithKline Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY, GB
LINDVALL, Miska, Kristian, GlaxoSmithKline Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY, GB
MITCHELL, Charlotte, Jane, GlaxoSmithKline Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY, GB
TRIVEDI, Naimisha, GlaxoSmithKline Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY, GB

PA

GLAXO GROUP LIMITED, Glaxo Wellcome House, Berkeley Avenue,, Greenford, Middlesex UB6 0NN, GB

PAS

GLAXO GROUP

PAN

GLAXOSMITHKLINE

AG

Gladwin, Amanda Rachel, GlaxoSmithKline Corporate Intellectual Property CN925.1 980 Great West Road, Brentford, Middlesex TW8 9GS, GB

LAF

English

LA

English

DT


Patent; (Fulltext)

PI

EP 1940835 B1 20110330

DS

R: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LU LV MC NL PT RO SE SK SI TR



	Drug	Common Drug Name	Database	Synonyms	Highest Phase	Companies	Last Update
1	Pretium	Pretium	Donec	Velut auctor Diam gravida Lobortis leo bibendum	Phase 3	Lobortis Turpis Aliquam Sodales	2012-11-17
2	Pretium XGS	Pretium	Loreset Sem	Velut auctor Diam gravida XS-2	Phase2	Lobortis Turpis Aliquam Sodales	2012-10-01
3	Sollicitudin 4S	Sollicitudin	Donec	Quam diam Augue sit Ametan id lacus	Phase 3	Egestas Condernum Lobortis Turpis	2011-12-07
4	Sollicitudin	Sollicitudin	Elitend-UR	Quam diam Augue sit Ametan id lacus	Phase 3	Egestas Condernum	2011-06-07
5	Etiam Mollis	Etiam Mollis	Loreset Sem	Adiscing Proin Mattis Faucibus lacus	Phase 3	Condernum Est	2012-01-13
6	Etiam Mollis	Etiam Mollis	Elitend-UR	Adiscing Et Sec Proin Mattis Faucibus	Phase 2	Condernum Est	2012-01-13
7	Toror Felis	Toror Felis	Donec	Aenean lectus purus Nulla sit amet Quisque placerat 2A	Phase 2	Loreset	2011-06-03
8	Toror Felis III	Toror Felis	Loreset Sem	Aenean lectus purus Quisque placerat	Phase 2	Loreset	2011-06-03
9	Consectetur	Consectetur	Donec	Purus non urna Ligula est Quam sem ac	Phase 3	Lobortis turpis	2012-03-01
10	Consectetur 2A	Consectetur	Nullam	Purus non urna Ligula est Quam sem ac	Phase 3	Lobortis turpis	2012-03-01

STNext Reports and Templates

EPFULL
Record

BIB AB
CLMEN

Custom
Template

BizInt
Definition

Columns

BizInt
Chart

STNext

Transcript ON2022_0013_Transcript

File EPPULL

L5

ANSWER 1 OF 1 EPPULL COPYRIGHT 2022 LNU on STN.

AN

1992589 EPPULL EDP 20210308 ED 20210308 UP 20211125 EDTX 20210308 DED 20110331 DUPO 20211118 Full-text

TIE

PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS

TIFR

COMPOSES DE PYRAZOLO[3,4-B]PYRIDINE ET LEUR UTILISATION COMME INHIBITEURS DE PDE4

TIDE

PYRAZOLO[3,4-B]PYRIDINVERBINDUNGEN UND IHRE VERWENDUNG ALS PDE4-INHIBITOREN

IN

EDLIN, Christopher, David, GlaxoSmithKline Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY, GB
HOLMAN, Stuart, GlaxoSmithKline Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY, GB
JONES, Paul, Spencer, GlaxoSmithKline Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY, GB
KEELING, Suzanne, Elaine, GlaxoSmithKline Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY, GB
LINDVALL, Miska, Kristian, GlaxoSmithKline Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY, GB
MITCHELL, Charlotte, Jane, GlaxoSmithKline Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY, GB
TRIVEDI, Naimisha, GlaxoSmithKline Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY, GB

PA

GLAXO GROUP LIMITED, Glaxo Wellcome House, Berkeley Avenue,, Greenford, Middlesex UB6 0NN, GB

PAS

GLAXO GROUP

PAN

GLAXOSMITHKLINE

AG

Gladwin, Amanda Rachel, GlaxoSmithKline Corporate Intellectual Property CN925.1 980 Great West Road, Brentford, Middlesex TW8 9GS, GB

LAF

English

LA

English

DT


Patent: (Fulltext)

PI

EP 1940835 B1 20110330

DS



R: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LU LV MC NL PT RO SE SK SI TR



	Drug	Common Drug Name	Database	Synonyms	Highest Phase	Companies	Last Update
1	Pretium	Pretium	Donec	Velut auctor Diam gravida Lobortis leo bibendum	Phase 3	Lobortis Turpis Aliquam Sodales	2012-11-17
2	Pretium XGS	Pretium	Loreset Sem	Velut auctor Diam gravida XS-2	Phase2	Lobortis Turpis Aliquam Sodales	2012-10-01
3	Sollicitudin 4S	Sollicitudin	Donec	Quam diam Augue du	Phase 3	Egestas Condimentum Lobortis Turpis	2011-12-07
4	Sollicitudin	Sollicitudin	Elifend-UR	Quam diam Augue du Ametan id lacus	Phase 3	Egestas Condimentum	2011-06-07
5	Etiam Mollis	Etiam Mollis	Loreset Sem	Adipiscing Proin Mattis Faucibus lacinula	Phase 3	Condimentum Egest	2012-01-13
6	Etiam Mollis	Etiam Mollis	Elifend-UR	Adipiscing Et Sec Proin Mattis Faucibus	Phase 2	Condimentum Egest	2012-01-13
7	Toror Felis	Toror Felis	Donec	Aenean lectus purus Nulla sit amet Quisque placerat 2A	Phase 2	Loreset	2011-06-03
8	Toror Felis II	Toror Felis	Loreset Sem	Aenean lectus purus Quisque placerat	Phase 2	Loreset	2011-06-03
9	Consectetur	Consectetur	Donec	Purus non urna Ligula est Quam sem ac	Phase 3	Lobortis turpis	2012-03-01
10	Consectetur 2A	Consectetur	Nullam	Purus non urna Ligula est Quam sem ac	Phase 3	Lobortis turpis	2012-03-01

Special Fields in Templates

- In addition to making sure your template includes all of your display fields, there are some additional fields you want to include.
- Answer Line and Answer Number are used to create the Record Num. column
- Full-Text gives you ChemPort links
- PatentPak Links is for the interactive link
- PatentPak Location is for Hit PPAK



Supported Files on STN

- CAplus, DWPI, IFIALL, MARPAT, REGISTRY
- **Full text:** USPATFULL/USPAT2, PCTFULL, EPFULL, CNFULL, DEFULL, FRFULL, GBFULL, INFULL, JPFULL, KRFULL, RUFULL, AUPATFULL, CANPATFUL
- **Gene Sequence:** GENESEQ, PATGENE, USGENE
- **Literature:** EMBASE, MEDLINE, BIOSIS, 1MOBILITY, AGRICOLA, ANABSTR, BIOTECHNO, CABA, COMPENDEX, DDFU/DRUGU, ENCOMPLIT, FSTA, GEOREF, INSPEC, IPA, KOSMET, METADEX, NTIS, PIRA, PQSCITECH, RAPRA, SCISEARCH, TEMA, TOXCENTER, TULSA

Unsupported Files on STN

- INPADOCDB, INPAFAMDB
- REAXYS, DCR
- APOLLIT, BIOTECHABS, CEABA, ESBIOBASE, NAPRALERT, WSCA, LITALERT, CROPU, PS, RTECS, VETU, CBNB, CIN ADISCTI/ADISINSIGHT/ADISNEWS, IMSRESEARCH
- CASFORM, CASREACT, DWPIM, CHEMCATS, CHEMLIST, GENBANK

Needed BizInt export

New/Reload

Interest?

Need model for tables

Unsupported Files on STN - coming soon

- INPADOCDB, INPAFAMDB
- MARPAT improvements, REAXYS, DCR
- APOLLIT, BIOTECHABS, CEABA, ESBIOBASE, NAPRALERT, WSCA, LITALERT, CROPU, PS, RTECS, VETU, CBNB, CIN ADISCTI/ADISINSIGHT/ADISNEWS, IMSRESEARCH
- CASFORM, CASREACT, DWPIM, CHEMCATS, CHEMLIST, GENBANK

Needed BizInt export

New/Reload

Interest?

Need model for tables

Tables, Records, and Links

Fields → Columns

Records → Rows

MEDLINE: stn_medl_willmore_epilepsy								
	Title	Record Num.	Author	Corporate Source	Document Type	Source	DOI	PMID
1	Monitoring and antiepileptic drug safety.	L5 ANSWER 1 OF 86	Willmore L James	Saint Louis University School of Medicine, 1402 South Grand Boulevard C-130, St Louis, MO 63104-1004, USA. mailto:willmore@slu.edu	(CASE REPORTS) Journal Article (JOURNAL ARTICLE) General Review (REVIEW)	Continuum (Minneapolis, Minn.), (2013 Jun) Vol. 19, No. 3 Epilepsy, pp. 801-5. Journal code: 9509333. E-ISSN: 1538-6899. L-ISSN: 1080-2371.	http://dx.doi.org/10.1212/01.CON.0000431392.31476.9e	23739112
2	Hippocampal gene expression profiling in a rat model of posttraumatic epilepsy reveals temporal upregulation of lipid metabolism-related genes.	L5 ANSWER 2 OF 86	Ueda Yuto Kitamoto Aya Willmore L James Kojima Toshio	Section of Psychiatry, Department of Clinical Neuroscience, Faculty of Medicine, University of Miyazaki, Miyazaki, 889-1692, Japan.	Journal Article (JOURNAL ARTICLE)	Neurochemical research, (2013 Jul) Vol. 38, No. 7, pp. 1399-406. Electronic Publication Date: 13 Apr 2013 Journal code: 7613461. E-ISSN: 1573-6903. L-ISSN: 0364-3190.	http://dx.doi.org/10.1007/s11064-013-1037-9	23585123
3	Posttraumatic epilepsy .	L5 ANSWER 3 OF 86	Da Silva A Martins Willmore L James	Hospital Geral de Santo Antonio and Biomedical Science Institute, University of Porto, Porto, Portugal.	Journal Article (JOURNAL ARTICLE)	Handbook of clinical neurology, (2012) Vol. 108, pp. 585-99. Journal code: 0166161. ISSN: 0072-9752. L-ISSN: 0072-9752.	http://dx.doi.org/10.1016/B978-0-444-52899-5.00017-4	22939055
4	Posttraumatic Epilepsy : What's Contusion Got to Do With It?.	L5 ANSWER 4 OF 86	Willmore L James	Department of Neurology and Psychiatry, Saint Louis University School of Medicine, St. Louis, MO.	Journal Article (JOURNAL ARTICLE)	Epilepsy currents, (2012 May) Vol. 12, No. 3, pp. 87-91. Journal code: 101135954. E-ISSN: 1535-7511. L-ISSN: 1535-7511. Report No.: PMC-PMC3367422.	http://dx.doi.org/10.5698/1535-7511-12.3.87	22690135

Tables, Records, and Links

MEDLINE: stn_medl_willmore_epilepsy								
	Title	Record Num.	Author	Corporate Source	Document Type	Source	DOI	PMID
1	Monitoring and antiepileptic drug safety.	L5 ANSWER 1 OF 86	Willmore L James	Saint Louis University School of Medicine, 1402 South Grand	(CASE REPORTS) Journal Article (JOURNAL	Continuum (Minneapolis, Minn.), (2013 Jun) Vol. 19, No. 3	http://dx.doi.org/10.1212/01.CON.0000431392.31476.9e	23739112
Records: stn_medl_willmore_epileps...								
1: Monitoring and antiepileptic drug safety.								
2	Hippocampal gene expression profiling model of posttraumatic epilepsy reveals ter upregulation of lipid metabolism-related							
3	Posttraumatic epile							
4	Posttraumatic Epile What's Confusion G With It?							

Monitoring and antiepileptic drug safety.
NLM AN: 23739112

Author: Willmore L James

Corporate Source: Saint Louis University School of Medicine, 1402 South Grand Boulevard C-130, St Louis, MO 63104-1004, USA. mailto:willmore@slu.edu

Source: Continuum (Minneapolis, Minn.), (2013 Jun) Vol. 19, No. 3 Epilepsy, pp. 801-5. Journal code: 9509333. E-ISSN: 1538-6899. L-ISSN: 1080-2371.

Document Type: (CASE REPORTS) Journal; Article; (JOURNAL ARTICLE) General Review; (REVIEW)

Abstract
Treatment of patients with **epilepsy** strives for complete seizure control without intolerable drug side effects. Independent of blood drug levels, toxic effects allow titration to efficacy; however, allergic reactions, metabolically or genetically determined drug-induced illnesses, and idiosyncratic effects of drugs, while rare, may be life-threatening. Monitoring is an attempt to detect serious systemic toxic reactions of antiepileptic drugs in time to intervene and protect patients. The process begins with the disclosure to patients and family members of all information required for an informed decision delivered within the framework of risks and benefits. This review provides guidance regarding designing a monitoring strategy for patients requiring chronic treatment with antiepileptic drugs.

PMC-PMC3367422

Behind each row is the original record with hit highlights

Note: Hit Highlights only available using BizInt report format

Hit Highlights only in **record** displays

Tables, Records, and Links

MEDLINE: stn_medi_willmore_epilepsy								
	Title	Record Num.	Author	Corporate Source	Document Type	Source	DOI	PMID
1	Monitoring and antiepileptic drug safety.	L5 ANSWER 1 OF 86	Willmore L James	Saint Louis University School of Medicine, 1402 South Grand Boulevard C-130 St Louis, MO 63104-1001 mailto:willm@slu.edu	(CASE REPORTS) Journal Article (JOURNAL ARTICLE) General	Continuum (Minneapolis, Minn.), (2013 Jun) Vol. 19, No. 3 Epilepsy pp. 801-5	http://dx.doi.org/10.1212/01.CON.0000431392.31476.9e	23739112
2	Hippocampal gene expression profiling model of posttraumatic epilepsy reveals ter upregulation of lipid metabolism-related			Section of Psychiatry, Department Clinical Neurosciences Faculty of Medicine University of Miyazaki, Miyazaki, 889-1692, Japan.		Journal code: 7613461. E-ISSN: 1573-6903. L-ISSN: 0364-3190.	10.1212/01.CON.0000431392.31476.9e	23585123
3	Posttraumatic epile			Hospital Geral de Santo Antonio and Biomedical Science Institute, University of Porto, Porto, Portugal.	Journal Article (JOURNAL ARTICLE)	Handbook of clinical neurology. (2012) Vol. 108, pp. 585-99. Journal code: 0166161. ISSN: 0072-9752. L-ISSN: 0072-9752.	http://dx.doi.org/10.1016/B978-0-444-52899-5.00017-4	22939055
4	Posttraumatic Epilepsy : What's Confusion Got to Do With It?.	L5 ANSWER 4 OF 86	Willmore L James	Department of Neurology and Psychiatry, Saint Louis University School of Medicine, St. Louis, MO.	Journal Article (JOURNAL ARTICLE)	Epilepsy currents. (2012 May) Vol. 12, No. 3, pp. 87-91. Journal code: 101135954. E-ISSN: 1535-7511. L-ISSN: 1535-7511. Report No.: PMC-PMC3367422.	http://dx.doi.org/10.5988/1535-7511-12.3.87	22690135

Row Properties

Database: MEDLINE (MEDL)

Date: 2014-01-08

Accession Number: 23739112

Row Status: Unchanged

Publisher URL:

https://chemport-n.cas.org/chemport-n/?PiA5w_ahQY04JLEbL6BxYUioCy6GNCMQFc2nsDRwJraQid390HavIE_2awuXp1jiniS43zC7nCIAAji1Vm

OK

Cancel

Each row also holds meta data such as Accession Number, Update Date, and link to full-text (ChemPort)

Editing Charts - Columns

- Select and rearrange columns in your table
- Add columns for your annotations

Choose Columns

Available Columns		Selected Columns
Application Details	>	Title
Basic Patent Number	>>	BizInt Common Family
Basic Publication Date	<	Patent Family
CA Doc Type	<<	Patent Assignee
Claims		Inventor(s)
BizInt Database		Priority Information
Document Number		Priority Date
DOI		BizInt New Publications
Entry Date		Record Num.
Family Status		
Full Text Link		
Hit Index Terms		
Index Terms		
Other Source		
Patent Family Status		
Publisher		
BizInt Row Status		
Source		
Status		
Update Date		
US Patent Number		

☐ Show empty columns (19 columns)

9 columns selected (of 51 in chart)

Up
Down

Apply Cancel Help

Editing Charts - Rows

- Select and rearrange rows in the report
- Quick “hide row” during review
- Sorting

The image shows two overlapping dialog boxes from a software application. The top dialog, titled "Display Rows", contains a list of 35 rows, each with a checkbox, a number, a code, and a description. All checkboxes are checked. To the right of the list are buttons for "Apply", "Select All", "Move Up", "Move Down", and "Cancel". The bottom dialog, titled "Sort Rows", has a "Columns:" list on the left with items like "Abstract", "Accession Number", "Agent", etc. It includes "Add >>" and "Remove" buttons. On the right, the "Sort Order:" section shows "Common Family" and "Priority Date" with a bar chart icon, and a "Sort" button. Below this are "Cancel" and "Help..." buttons. At the bottom right of the "Sort Rows" dialog is a checkbox labeled "Alternate row shading when primary sort key changes" which is checked.

Display Rows

35 rows, 35 selected

Sort Rows

Columns:

- Abstract
- Abstract (French)
- Accession Number
- Agent
- Basic Patent Number
- Basic Publication Date
- CA Classification
- CA Doc Type
- Claims
- CPC
- Database
- Dates
- Document Number
- DOI
- ECLA Class
- Entry Date
- Full Text Link
- Hit Registry Numbers
- Index Terms

Sort Order:

- Common Family
- Priority Date

Buttons: Apply, Select All, Move Up, Move Down, Cancel, Add >>, Remove, Ascending, Sort, Cancel, Help...

Checkbox: ☒ Alternate row shading when primary sort key changes

Exporting

- Most BizInt Smart Charts users deliver results via Word or Excel

Excel

Excel


A1						
	A	B	C	D	E	F
1	Natamycin_caplus_2021 up2					
2		Title	Row Status	Patent Assignee	Priority Date	Patent Fa (Patent : Kind)
3	1 Link	Preparation of novel imidazole derivative salt as antifungal agent	Added	University-Industry Cooperation Group of Kyung Hee University, S. Korea	9/3/2020	WO 2022050774 : A1 : 2 KR 2022030520 : A : 2022
4	2 Link	Inhalable therapeutic agents	Added	Cila Therapeutic Inc., USA	8/26/2020	WO 2022047047 : A1 : 2
5	3 Link	Compositions, devices and methods for treating nasal, otic and other tissue infection and/or inflammation	Added	Oticara, Inc., USA	8/26/2020	WO 2022047042 : A1 : 2
6	4 Link	Engineering of TIGIT antibodies for treatment of fungal infections	Added	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., Israel	8/26/2020	WO 2022044010 : A1 : 2
7	5 Link	Antimicrobial composition that preserves the organoleptic conditions of fruit and vegetables	Added	Chile	8/10/2020	WO 2022032402 : A1 : 2
8	6 Link	Composition for use in the treatment of viral infections	Added	BiCT S.r.l., Italy	8/3/2020	WO 2022029577 : A1 : 2
9	7 Link	A pesticidally active mixture comprising pyrazolopyridine anthranilamide compound, oxides or salts thereof, with insecticides or fungicides	Added	PI Industries Ltd., India	7/27/2020	WO 2022023931 : A1 : 2

Summary Records in Word

1. Title: Novel all-trans polyene amphoteric macrolide and process for purifying natamycin
 Priority Date: 2018-08-16
 Patent Assignee: DSM IP Assets B.V., Neth.
 New Publications: EP 3837270 A1; US 2021230207 A1

FTO Family:	Pub No.	Kind	Pub Date	Status
	EP 3837270	A1	2021-06-23	PENDING
	WO 202035552	A1	2020-02-20	LAPSED
	US 20210230207	A1	2021-07-29	PENDING
	CN 112543761	A	2021-03-23	PENDING

Graphic Information:



Database: [Chemical Abstracts](#)
[FAMPAT](#)

Hyperlinks: [Source](#) | [WO 2020035552 A1](#) | [PatDocs Family Tree](#) | [PatentPak Interactive](#)

Notes

Claims:

(WO2020/035552)

1. A process for purifying **natamycin** comprising mixing a composition comprising crude **natamycin**, a metal salt of a carboxylic acid and water and subjecting the resulting mixture to chromatography whereby fractions are collected and selected fractions that comprise **natamycin** are combined, wherein the amount of said crude **natamycin** is from 1 g to 100 g/kg of the total weight of said composition and wherein the concentration of said metal salt of a carboxylic acid is from 0.1 mol/L to 5 mol/L.

6. (1 R,3S,5EJR, 1 1 R, 13E, 15 E, 17 E, 19E,21 R,23S,24R,25S)-21 -[3-Amino-3,6-dideoxy- -D-mannopyranosyl]oxy]-1 ,3,7,25-tetrahydroxy-1 1-methyl-9-oxo-10,27-dioxabicyclo[21.3.1]- heptacos-5, 13, 15, 17, 19-pentaene-24-carboxylic acid of formula (II) or a salt thereof.

Combine Charts

- Combine two or more charts into a single report
- Only one copy of true duplicates (same DB, same AN) in the resulting chart
- Similar fields mapped in one column (e.g. AU and IN)
- Combined chart created from a multi-file transcript in a single step

Create Combined Chart Wizard


Step 2 - Select charts to be combined:

Key chart: Patent Forum Example

Charts to be combined: Patent Forum EP

Chart file information:

Natamycin_captus_orbit sumrec
Combined: 2 records
Unsaved
Last modified: April 14, 2022 4:22:16 pm



Combine Charts - Uses

- Combine different search strategies
- Combine results from different files
- Combine searches run at different times
- **Best practice:** save your chart files!
- Combine results from different databases and hosts
e.g. STNext with CAS Biosequences on GenomeQuest

Supported databases & hosts:

BizInt Smart Charts

for Patents

- **Patents:**
STN, Orbit.com, PatBase, Derwent Innovation, Cortellis & CDDI, LifeQuest
- **IP Sequence:**
STN, GenomeQuest, Orbit BioSequence
- **Non-patent Literature:**
STN, SciFinder, Dialog, Ovid, PubMed

See: bizint.com/product/patents/supported_dbs.php



Integrate Results

BizInt Smart Charts

Reference Rows™

- Deals with “dups” - records referring to the same family
- Rows grouped based on Common Patent Family
- Value in each column is selected by rules
 - “Fill in the blanks”
 - Database preference
 - Content-based rules
 - Summarize rules

Common Patent Family

- Rows grouped based on publication numbers in the patent family
- Numbers are normalized
- Linkage is transitive builds a “super-family”
- Some other family information is considered in limited cases

Database	Common Family	Patent Family		
		Patent	Kind	Date
Derwent World Patents Index	US 2014356956	US20140356959	A1	20141204
		US20140356956	A1	20141204
Derwent World Patents Index	US 2014356956	WO2014197568	A2	20141211
		WO2014197568	A3	20150312
		CA2914638	A1	20141211
FAMPAT	US 2014356956	US 2014356956	A1	2014-12-04
		US 2014356959	A1	2014-12-04
		US 2014356956	B2	2016-02-23
GQPAT Gold+ Proteins	US 2014356956	US20140356959		20141204
GQPAT Gold+ Proteins	US 2014356956	US20140356956		20141204
PatBase	US 2014356956	US 2014356959	A	2014-12-04
		US 2014356956	A	2014-12-04
		AO 2014274939	AA	2014-12-11
		WO 14197568	A2	2014-12-11
		WO 14197568	A3	2015-03-12
		CA 2914638	AA	2015-12-04
		KR 20160014036	A	2016-02-05

therapeutic uses of substituted quinoxalines

Title	Common Family	Database	Patent Assignee	Patent Family			Claims	Hit Index Terms			
				Patent	Kind	Date		RN	Role	Notes	
1. Preparation of 1H-pyrazolo[3,4-b]pyridines as phosphodiesterase, especially PDE4B, inhibitors for treatment of inflammatory and/or allergic diseases	WO 2007036733	1a	CA link	Glaxo Group Limited, UK	WO 2007036733	A1	20070405	A compound of formula (I) or a salt thereof (in particular, a pharmaceutically acceptable salt thereof):wherein: R _{sp1} is C1-3a[kyl, C1-3fluoroalkyl, or-CH2CH2OH; R _{sp2} is a hydrogen atom (H), methyl, ethyl, n-propyl, isopropyl, n-butyl, C1-2fluoroalkyl, cyclopropyl, cyclobutyl, (cyclopropyl)methyl-, cyano (-CN), or -CH2OH; [CONT.]	932112-07-7P	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)	prepn. of pyrazolo[3,4-b]pyridines as PDE4 inhibitors for treatment of inflammatory and/or allergic diseases
		1b	EP		EP 1940835	A1	20080709				
		EP 1940835	B1		20110330						
		JP 2009510043	T		20090312						
		JP 5323484	B2		20131023						
		AT 503756	T		20110415						
		ES 2363795	T3		20110816						
		US 20090131431	A1		20090521						
2. Preparation of aminoquinoxalines and aminoquinolines as adenosine A2A receptor antagonists	WO 2009111442	1a	CA	Corporation,	WO 2009111442	A1	20090911	A compound represented by the structural Formula I:wherein: W represents N; Z represents halogen or haloalkyl; Q represents -CONHR _{sp1} ; or represents a heterocyclic radical selected from the group consisting of: R _{sp1} represents aralkyl, aryloxyalkyl, benzocycloalkyl or heteroarylalkyl; and R _{sp2} represents amino, aryl, heteroaryl, arylamino, arylalkyl or heteroarylalkyl; n is an integer from 0-4; [CONT.]	1186469-01-1P 1186469-12-4P 1186469-18-0P 1186469-32-8P	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)	prepn. of aminoquinoxalines and aminoquinolines as adenosine A2A receptor antagonists
		2a	CA		AU 2009222040	A1	20090911				
		CA 2717171	A1		20090911						
		EP 2282999	A1		20110216						
		EP 2282999	B1		20140521						
		JP 2011514350	T		20110506						
		US 20110105513	A1		20110505						
		US 8415353	B2		20130409						
3. Synthesis of indole antivirals binding to FABP4 treating coronavirus infections	WO 2022010951	3	CA link	Crescenta Biosciences, USA	WO 2022010951	A1	20220109	2757684-69-6P	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)	synthesis of FABP4 binding indole antivirals treating coronavirus infections	
		3a	CA		US 20210174288	A1	20210927				
		CA 3057431	A1		20180927						
		AU 2018239711	A1		20191107						
		CN 110446699	A		20191112						
		KR 2019133667	A		20191203						
		EP 3604281	A1		20200205						
		US 20210070747	A1		20210311						
4. Preparation of 2(1H)-quinolinone derivatives having antimicrobial activity	WO 2018174288	4a	CA link	Taisho Pharmaceutical Co., Ltd., Japan	WO 2018174288	A1	20180927	A compound represented by the structural formula (I) (wherein Z represents an alkyl group (said C1 substituted with an hydroxy group) or a hydroxy group; R _{sp1} represents a hydrogen atom or a C1-4 alkyl group; T, U, V and W all represent C-R _{sp2} or either one of them represents N while the other represent C-R _{sp2} ; [CONT.]	2757684-69-6P	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)	prepn. of 2(1H)-quinolinone derivs. useful as antimicrobial agents
		4b	EP		CA 3057431	A1	20180927				
		AU 2018239711	A1		20191107						
		CN 110446699	A		20191112						
		KR 2019133667	A		20191203						
		EP 3604281	A1		20200205						
		US 20210070747	A1		20210311						
		IN 201917041011	A		20191115						
ZA 2019006699	A	20210224									

Agenda

- Basics of Building Reports
- Advanced Uses
 - Updates and Alerts
 - Color Coding
 - Hit Structures and PatentPak
 - Sequences



Update

- Update is a special version of Combining charts
- **Row Status**: is this a new row or have you seen it before?
- Which cells changed?
- Are there **new publications** in the patent family?
- Uses:
 - Integrate alerts into your ongoing reports
 - See what has changed since the last report

Update

	Title	Row Status	Patent Assignee	Priority Date	Patent Family			New Publications	Date?	Region?
					Patent	Kind	Date			
37	Preparation of novel imidazole derivative salt as antifungal agent	Added	University-Industry Cooperation Group of Kyunghee University, S. Korea	2020-09-03	KR 2022030520 WO 2022050774	A A1	20220311 20220310	KR 2022030520 A WO 2022050774 A1		
38	Bactericidal agent for agricultural or horticultural use, plant disease control method, and product for plant disease control use	Updated	Kureha Corporation, Japan	2019-04-19	WO 2020213739 CA 3135695 JP 6942284 KR 2021141781 CN 113727606 AU 2020257751 AU 2020257751 CR 20210543 EP 3957177 IN 202117048015 CO 2021015225	A1 A1 B2 A A A1 B2 A A1 A A2	20201022 20201022 20210929 20211123 20211130 20211202 20220324 20211215 20220223 20220218 20211130	KR 2021141781 A CN 113727606 A AU 2020257751 A1 AU 2020257751 B2 CR 20210543 A EP 3957177 A1 IN 202117048015 A CO 2021015225 A2		
39	Agricultural mixtures comprising carboxamide compound		LSF SE, Germany	2013-10-18	V C C A A IL KR 2016072216 KR 2310373 AR 99276 EP 3057419 EP 3057419 IN 201647013246 IN 375329 CN 105939603 CN 105939603 JP 2016535007 JP 6644670	A B1 A1 A1 B1 A B A B T B2	20160622 20211008 20160713 20160824 20210728 20160831 20210825 20160914 20210622 20161110 20200212	00 A A1		


Update status of each row

List new publications since previous version

Color codes in user columns preserved

Color Coding Cells

- Color code cells in one of eight colors
- Colored cells in user-added columns survive Combine and Update, even if the row is updated
- Useful for FTO analysis
see June 2021 presentation
at bizint.com/events/webinars.php



[illegible]

HITSTR


- Hit structures are available in the Summary Records export
- Options:
 - Hit structures with each reference
 - Index of Hit Structures for the entire report
 - Index terms (linked to Index of Hit Structures)

HITSTR - Index of Hit Structures

Index of Hit Structures

Substance	Structure	Reference
1 2757684-69-6 2(1H)-Quinoxalinone, 8-chloro-3- [[2-[(3,5-dichlorophenyl)methyl]- 1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)		synthesis of FABP4 binding indole antivira treating coronavirus infections Reference 1 (Pg 91)
2 2415831-50-2 2-Quinoxalinecarboxamide, 6- fluoro-3,4-dihydro-3-oxo- (CA INDEX NAME)		synthesis of substituted quinoxalines as anti-coronavirus agent Reference 2

Each structure
with all references
in which it occurs

Priority Information:	Application	Date
	US 2020-63048609	20200706
Priority Date:	2020-07-06	
New Publications:		
Hyperlinks:	Source	WO 2022010951 A1 PatDocs Family Tree PatentPak Interactive
Notes		
Hit Structures:		
2757684-69-6 (Cmpd. 1 - Pg 91) 2(1H)-Quinoxalinone, 8-chloro-3-[[2-[(3,5-dichlorophenyl)methyl]-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)		RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) synthesis of FABP4 binding indole antivirals treating coronavirus infections
Index Terms:		
2757684-69-6P (Cmpd. 1) Pg 91 PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (synthesis of FABP4 binding indole antivirals treating coronavirus infections)		

Hit Structures
with each record

Index terms
linked to Index

PatentPak

- PatentPak Interactive link available as a column or in the links section in a summary record.
- Hit PPAK links available as a table in a column, or in summary records with the Index Term, Hit Structures, or Index of Hit Structures.



PatentPak Links



PatentPak Patent Information





PatentPak Location



PatentPak Support


Hit PatentPak		Hit Index Terms PPAK		
RN	Location	RN	Role	Notes
1655492-02-6P	Pg 85	1655492-02-6P (Pg 85)	RL: RCT (Reactant); SPN (Synthetic preparation);	prepn. and anti-mycobacterial

Index of Hit Structures

Substance	Structure	Reference
1 1655492-02-6 2,1-Benzoxaborole, 4-fluoro-1,3-dihydro-1-hydroxy-3-(nitromethyl)-7-[2-(phenylmethoxy)ethoxy]- (CA INDEX NAME)		prepn. and anti-mycobacterial activity of benzoxaborole compds. Reference 1 (Pg 85)
2 1364682-96-1 1-Propanol, 3-[[[3-(aminomethyl)-4-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborol-7-yl]oxy]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)		prepn. and biol. applications of tricyclic benzoxaborole compds. Reference 2 (Pg 62)

Hit Structures:

1655492-02-6 [\(Cmpd. 1\) \(Pg 62\)](#)
2,1-Benzoxaborole, 4-fluoro-1,3-dihydro-1-hydroxy-3-(nitromethyl)-7-[2-(phenylmethoxy)ethoxy]- (CA INDEX NAME)



RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

prepn. and biol. applications of tricyclic benzoxaborole compds.

Index Terms:

1655492-02-6P [\(Cmpd. 1\) \(Pg 62\)](#) RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (prepn. and biol. applications of tricyclic benzoxaborole compds.)

Sequence Searches

- Each row contains a sequence alignment in the context of a query
- Use Reference Rows to summarize hits by family
- Standardized Sequence identifier across databases
- Recipes at bizint.com/piugbio

WO2018071345-0006	LCDR1	100.00	5.2
WO2018071345-0005	HCDR3	100.00	5.3
WO2018071345-0001	HCDR3	14.84	5.4
WO2018071345-0004	HCDR2	100.00	5.5
WO2018071345-0001	HCDR2	13.28	5.6
WO2018071345-0008	LCDR3	100.00	5.7
WO2018071345-0002	LCDR3	8.49	5.8
WO2018071345-0003	HCDR1	100.00	5.9
WO2018071345-0007	LCDR2	100.00	5.10
WO2018071345-0002	LC-Ebola	100.00	5.11
WO2018071345-0001	HC-Ebola	100.00	5.12

CAS Biosequences on GenomeQuest

CAS Biosequences: gqreport_bizint (2)										
	Title	Query ID	Patent Sequence Location	Alignment	Seq. Identifier	CAS Registry Number	CAS Name	Role		
1	Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof	LCDR1	SEQID 28; claimed	Q: 1 RASQISNNLA 11 S: 1 RASQISNNLA 11	WO2014115893-0028	1428524-37-1	L-Alanine, L-arginyl-L-alanyl-L-seryl-L-glutaminyl-L-seryl-L-isoleucyl-L-seryl-L-asparaginy-L-asparaginy-L-leucyl-	Biological Study, Unclassified; Properties; Biological Study	linear	
2	Preparation of anti-human TL1a antibodies for diagnosis, prevention and treatment of TL1a-mediated autoimmune disease	LCDR1	SEQID 15; unclaimed	Q: 1 RASQISNNLA 11 S: 1 RASQISNNLA 11	WO2013044298-0015	1428524-37-1	L-Alanine, L-arginyl-L-alanyl-L-seryl-L-glutaminyl-L-seryl-L-isoleucyl-L-seryl-L-asparaginy-L-asparaginy-L-leucyl-	Properties	linear	
3	Broadly neutralizing antibody targeting the ebolavirus glycoprotein internal fusion loop	LCDR1	SEQID 6; claimed	Q: 1 RASQISNNLA 11 S: 1 RASQISNNLA 11	WO2018071345-0006	1428524-37-1	L-Alanine, L-arginyl-L-alanyl-L-seryl-L-glutaminyl-L-seryl-L-isoleucyl-L-seryl-L-asparaginy-L-asparaginy-L-leucyl-	Biological Study, Unclassified; Properties; Biological Study	linear	
4	Broadly neutralizing antibody targeting the ebolavirus glycoprotein internal fusion loop	HCDR3	SEQID 5; claimed	Q: 1 DPGFTIFGWITSWSGLDS 19 S: 1 DPGFTIFGWITSWSGLDS 19	WO2018071345-0005	2222535-23-9	L-Serine, L-aspartyl-L-prolylglycyl-L-phenylalanyl-L-threonyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-isoleucyl-L-isoleucyl-L-threonyl-L-seryl-L-threonine-	Biological Study, Unclassified; Properties; Biological Study	linear	

Multiple Queries

Sequence/Alignment

CAS Indexing

Try it yourself!

Free trial of the full customer software available at bizint.com

Software for Business Intelligence

BizInt Smart Charts

Home Products Support Resources About Us Contact Us

help: support@bizint.com

Customer Software Try It!

Try it with your data!
Sign up for a free trial, and get started creating reports and visualizations!
[Learn more »](#)

Upcoming Events
PIUG Annual Conference
May 1-4, 2022
Alexandria, VA (USA)
[2022 conferences & events »](#)

Patents & IP Sequences Drug Pipelines & Clinical Trials Analytics & Visualization

BizInt Smart Charts
for Patents

Create, customize and distribute tabular reports integrating data from the leading patent, IP sequence, and scientific/technical literature databases and hosts.

- Product information »
- Mini Guide »
- Latest release information »
- Supported databases »
- BizInt Smart Charts brochure »

DOWNLOADS:

- Download customer software »
- Sign up for free trial software »

About BizInt Smart Charts
Since 1996, BizInt Smart Charts software has helped analysts create, customize and distribute reports and visualizations from these types of databases:

- drug pipeline & clinical trial
- patent & IP sequence
- scientific/technical literature

BizInt Smart Charts product family is used by pharmaceutical, biotech, chemical and other technology companies worldwide.



Software for
Business Intelligence

BizInt Smart Charts

Questions?



THE JOURNEY CONTINUES